Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.


0.5 stars

302 Reads | 0 Comments | 0 People call this a favourite


  • T.PLI:new price target! 3.25$.

    218 Reads | 1 Comment | May 8, 2015

    Canaccord: Buy rating and $3.25 target price for ProMetic According to Canaccord Genuity:   ProMetic Life Sciences Inc.   RATING: BUY (unchanged)   PRICE TARGET: C$3.25↑ from C$3.00   Raising Target Price   Identifying yet another opportunity: ProMetic adds C1-INH to its pipeline  ...

  • T.PLI:Closing of $50 M Bought Deal Offering of Common Shares

    246 Reads | 0 Comments | May 6, 2015

    some shares still available below that price of 2.60$ at market;) ProMetic Announces Closing of $50 M Bought Deal Offering of Common Shares LAVAL, QUEBEC--(Marketwired - May 6, 2015) - ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the "Corporation") closed today its previously announced bought deal public offering of common shares in the capital of...

  • T.PLI:IR comments on the 50M$ financing...

    241 Reads | 1 Comment | April 17, 2015

    Here is Fred's answerers to a couple of questions I had about the recent financing announcement. Hi Doug, To the contrary, things are going on very well at PLI. The financing was rendered necessary for a few reasons:   1- We needed to have a balance sheet and a cash position that is more in line with our market cap, compared to our peers and with industry standards for a...

  • T.PLI:BNN: we're top pick #1

    209 Reads | 0 Comments | March 19, 2015

    TOP Pick Today

  • T.PLI:article:PLI celebrates diabetic kidney disease drug milestone

    251 Reads | 1 Comment | September 3, 2014

    ProMetic Life Sciences (T.PLI) celebrates diabetic kidney disease (DKD) drug milestone   ProMetic Life Sciences (TSX: PLI, Stock Forum) celebrated another important milestone in the regulatory journey for its anti-fibrotic, lead drug candidate, PBI-4050, when the company announced today that it had a successful Pre-Investigational New Drug (“Pre-IND”) meeting with the...

  • T.PLI:BNN/market call comments, aug 29

    325 Reads | 1 Comment | September 2, 2014

    Top Picks: Prometic Life Sciences (PLI.TO 1.48 0.00 0.00%) Prometic is a manufacturing company with the bonus of PBI-4050 ,an interesting drug discovery. PLI has proprietary filtering technology used for large scale purification of drugs and is using this technology to extract proteins from plasma at their plant in Laval, Quebec. Clinical studies of three proteins...

  • T.PLI:PLI on BNN/market call

    300 Reads | 0 Comments | August 29, 2014 about the 2 minute mark

  • T.PLI:cantech letter:PLI offers compelling risk/reward scenario, says Paradigm

    570 Reads | 0 Comments | August 28, 2014

    Prometic Life Sciences offers compelling risk/reward scenario, says Paradigm   August 20, 2014 By Nick Waddell 0 Comments Share this: 2 0 0 ProMetic Life Sciences (TSX:PLI) offers a truly compelling risk/reward scenario, says Paradigm Capital analyst Alan Ridgeway. Last Thursday, ProMetic reported its Q2, 2014 results. The company posted revenue of $4.4-million,...